Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

March 31, 2020

Conditions
Congenital Heart DiseasePulmonary Arterial Hypertension
Interventions
DRUG

Sildenafil singly or in association with Bosentan

Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.

Trial Locations (1)

05403-900

Instituto do Coração (InCor) HCFMUSP, São Paulo

All Listed Sponsors
collaborator

Instituto do Coracao

OTHER_GOV

collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

University of Sao Paulo General Hospital

OTHER

NCT01548950 - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension | Biotech Hunter | Biotech Hunter